This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of ascending doses administered once daily for 14 days in healthy volunteers.
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
39
PF-04958242 0.05 mg oral solution Q24 hours for 14 days
PF-04958242 0.10 mg oral solution Q24 hours for 14 days
PF-04958242 0.15 mg oral solution Q24 hours for 14 days
Pfizer Investigational Site
New Haven, Connecticut, United States
Composite of Pharmacokinetics measured at 0.25, 0.5, 0.75, 1, 2, 3, 4, 8, 12, 24 hours after dosing on Day 1
Time frame: Day 1-Day 2
Composite of Pharmacokinetics measured pre-dose and 1 hour post-dose on Day 4
Time frame: Day 4
Composite of Pharmacokinetics measured pre-dose and 1 hour post-dose on Day 7
Time frame: Day 7
Composite of Pharmacokinetics measured at 0.25, 0.5, 0.75, 1, 2, 3, 4, 8, 12, 24, 48, 72, 120 hours after dosing on Day 14
Time frame: Day 14-Day 18
Composite of urine Pharmacokinetics measured for 24 hours post-dose on Day 14
Time frame: Day 14-Day 15
Drug Effect Questionaire Liking scale
Time frame: Day 14
Digit Symbol Substitution Test
Time frame: Day 14
Columbia Suicide Severity Rating Scale
Time frame: Day 0-Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
PF-04958242 0.25 mg oral solution Q24 hours for 14 days
Placebo oral solution Q24 hours for 14 days